Title:
ANTI- CONNECTIVE TISSUE GROWTH FACTOR AGENT FOR USE IN THE TREATMENT OF LUNG REMODELING DISEASE
Document Type and Number:
WIPO Patent Application WO/2012/061811
Kind Code:
A3
Abstract:
The present disclosure relates to methods and medicaments useful for pre - treatment, treatment, or amelioration of lung remodeling disease. Methods and medicaments for reducing, preventing, or reversing increased lung density, improving lung function, and increasing survivability in subjects having lung remodeling disease are also provided.
Inventors:
LIPSON KENNETH E (US)
Application Number:
PCT/US2011/059589
Publication Date:
June 28, 2012
Filing Date:
November 07, 2011
Export Citation:
Assignee:
FIBROGEN INC (US)
LIPSON KENNETH E (US)
LIPSON KENNETH E (US)
International Classes:
A61K39/395; A61P11/00; C07K16/22
Domestic Patent References:
| WO2011056234A1 | 2011-05-12 |
Foreign References:
| US7405274B2 | 2008-07-29 |
Other References:
S. BICKELHAUPT ET AL.: "Attenuation and reversal of radiation-induced pulmonary fibrosis in a murine model by an anti-CTGF monoclonal antibody.", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY * BIOLOGY * PHYSICS, vol. 78, no. 3, suppl. S, 2010, pages S40, XP027318380
N. BHATT ET AL.: "Promising pharmacologic innovations in treating pulmonary fibrosis.", CURRENT OPINION IN PHARMACOLOGY, vol. 6, no. 3, June 2006 (2006-06-01), England, pages 284 - 292, XP025229624
V. THANNICKAL ET AL.: "Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy.", EXPERT OPINION ON PHARMACOTHERAPY, vol. 5, no. 8, August 2004 (2004-08-01), England, pages 1671 - 1686, XP008088927
M. AHMED ET AL.: "Induction of pulmonary connective tissue growth factor in heart failure is associated with pulmonary parenchymal and vascular remodeling.", CARDIOVASCULAR RESEARCH, vol. 74, no. 2, 1 May 2007 (2007-05-01), The Netherlands, pages 323 - 333, XP022033859
M. PONTICOS ET AL.: "Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen.", ARTHRITIS AND RHEUMATISM, vol. 60, no. 7, July 2009 (2009-07-01), U.S.A., pages 2142 - 2155, XP002667088
T-C. LAI ET AL.: "Small interfering RNAs (siRNAs) targeting TGF-beta1 mRNA suppress asbestos-induced expression of TGF-beta1 and CTGF in fibroblasts.", JOURNAL OF ENVIRONMENTAL PATHOLOGY, TOXICOLOGY AND ONCOLOGY, vol. 28, no. 2, 2009, U.S.A., pages 109 - 119, XP008147353
N. BHATT ET AL.: "Promising pharmacologic innovations in treating pulmonary fibrosis.", CURRENT OPINION IN PHARMACOLOGY, vol. 6, no. 3, June 2006 (2006-06-01), England, pages 284 - 292, XP025229624
V. THANNICKAL ET AL.: "Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy.", EXPERT OPINION ON PHARMACOTHERAPY, vol. 5, no. 8, August 2004 (2004-08-01), England, pages 1671 - 1686, XP008088927
M. AHMED ET AL.: "Induction of pulmonary connective tissue growth factor in heart failure is associated with pulmonary parenchymal and vascular remodeling.", CARDIOVASCULAR RESEARCH, vol. 74, no. 2, 1 May 2007 (2007-05-01), The Netherlands, pages 323 - 333, XP022033859
M. PONTICOS ET AL.: "Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen.", ARTHRITIS AND RHEUMATISM, vol. 60, no. 7, July 2009 (2009-07-01), U.S.A., pages 2142 - 2155, XP002667088
T-C. LAI ET AL.: "Small interfering RNAs (siRNAs) targeting TGF-beta1 mRNA suppress asbestos-induced expression of TGF-beta1 and CTGF in fibroblasts.", JOURNAL OF ENVIRONMENTAL PATHOLOGY, TOXICOLOGY AND ONCOLOGY, vol. 28, no. 2, 2009, U.S.A., pages 109 - 119, XP008147353
Attorney, Agent or Firm:
BORCHARDT, Paul, E. (Inc.409 Illinois Stree, San Francisco CA, US)
Download PDF:
Previous Patent: BASE MODIFIED OLIGONUCLEOTIDES
Next Patent: THERMOELECTRIC RECOVERY AND PELTIER HEATING OF ENGINE FLUIDS
Next Patent: THERMOELECTRIC RECOVERY AND PELTIER HEATING OF ENGINE FLUIDS